PARGY-LAD

propargyllysergic acid diethylamide

6Node page

what any key link opens

psx:substance/pargy-lad/section/summary.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

informed_byClaim in summary — inconclusivepsx:substance/pargy-lad/claim/e1c3d4f6-b411-4ba4-869d-e2db125a842f
informed_byClaim in summary — inconclusivepsx:substance/pargy-lad/claim/c69aed74-b4a0-44b1-872f-50819788fea3
informed_byClaim in summary — supportedpsx:substance/pargy-lad/claim/86a9c513-237d-4be8-ae0b-5b8bf7cdc36f
informed_byClaim in summary — partially_supportedpsx:substance/pargy-lad/claim/d8840861-c0d9-4138-a2ab-012e2de60239

feeds · downstream

none recorded

psx:substance/pargy-lad/section/summary.full@1
├─ informed_by  claim/e1c3d4f6-b411-4ba4-869d-e2db125a842f  Claim in summary — inconclusive  working
├─ informed_by  claim/c69aed74-b4a0-44b1-872f-50819788fea3  Claim in summary — inconclusive  working
├─ informed_by  claim/86a9c513-237d-4be8-ae0b-5b8bf7cdc36f  Claim in summary — supported
├─ informed_by  claim/d8840861-c0d9-4138-a2ab-012e2de60239  Claim in summary — partially_supported
  ├─ used  src/doi:10.1021/jm00147a022  Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives
  ├─ used  src/doi:10.1124/pr.115.011478  Psychedelics
  ├─ used  src/doi:10.1016/j.neuron.2025.06.012  The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
  ├─ used  src/doi:10.1021/acschemneuro.2c00170  Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
      ├─ used  src/url:d39c060e9934d744  PARGY-LAD — PsychonautWiki
      ├─ used  src/url:23284f423c322935  Reports on PARGY-LAD (newly offered lysergamide) — Bluelight.org
      ├─ used  src/url:a7b0465d79b6efbb  PARGY-LAD — Wikipedia
      ├─ used  src/pmid:139030999  PARGY-LAD PubChem Compound Entry
      ├─ used  src/doi:10.1016/j.cell.2020.08.024  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
      ├─ used  src/doi:10.1016/j.cell.2016.12.033  Crystal Structure of an LSD-Bound Human Serotonin Receptor
      ├─ used  src/doi:10.1002/dta.2222  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
      ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ used  src/doi:10.1007/s40262-017-0513-9  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
      ├─ used  src/doi:10.1111/bcp.13918  Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
      ├─ used  src/doi:10.1007/s00216-018-1558-9  In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
      ├─ used  src/doi:10.1002/dta.1985  Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
      ├─ used  src/doi:10.1073/pnas.2416106122  Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
      ├─ used  src/doi:10.1002/hup.2599  Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
      ├─ used  src/doi:10.1002/dta.3281  Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
      ├─ used  src/doi:10.1007/s00204-025-04255-1  The toxicity of psychedelic LSD derivatives: in silico approach for 1cP-LSD and analogs
      ├─ used  src/doi:10.1016/s0376-8716(03)00036-8  Hallucinogen persisting perception disorder: what do we know after 50 years?
      ├─ used  src/doi:10.1080/14740338.2022.2063273  Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
      ├─ used  src/doi:10.1007/7854_2016_457  A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
      ├─ used  src/pmid:16051647  Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
      ├─ used  src/doi:10.1177/0897190013504957  Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
      ├─ derived_from  gen/cd9b94c8-0423-4c15-9310-2714294d9a0c  Generation — pipeline-v5
      └─ generated_by  pub/aad61c78-1889-4631-b42b-89dcac2783cd  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/c422b34c-8276-4c48-8c8f-e61b693b565e  Claim in history — inconclusive  working
    ├─ used  claim/96d4dc18-44fa-4e85-83b0-41d2a0eb86c3  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/0ee6b34f-5757-458d-9321-48f51533b6a6  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/032ac6e4-e4c3-4f91-9f65-cbea4a9b9c38  Claim in pharmacology — inconclusive  working
    ├─ used  claim/d113bd52-2142-4041-8874-c7d1f40c0f28  Claim in safety — inconclusive  working
    ├─ used  claim/786bbdef-827f-4a37-a76b-1dff39e66d81  Claim in safety — inconclusive  working
    ├─ used  claim/f7bef47e-f1a5-4390-92fd-b93b6932acce  Claim in safety — inconclusive  working
    ├─ used  claim/ce447ecf-4a66-48d2-9d12-9d8ddd82d224  Claim in safety — inconclusive  working
    ├─ used  claim/599653eb-2785-4adc-afb2-92d0c5af6717  Claim in chemistry — inconclusive  working
    ├─ used  claim/28ca80eb-20f5-4f7d-87d7-36cd068c2955  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/1b772c79-3aa0-45e9-8402-b68ec405df55  Claim in neuroscience — inconclusive  working
    ├─ used  claim/e0fc4965-4cf4-411c-9798-a7bb022dc82d  Claim in pharmacology — supported
    ├─ used  claim/e7f7b4a2-c745-46d9-8b8f-b1930efce821  Claim in pharmacology — supported
    ├─ used  claim/8f94dc76-c63e-49c0-8018-b273fcbbd0a4  Claim in receptor-pharmacology — supported
    ├─ used  claim/fa782ea2-4caa-40b5-b37b-e196c3b25aae  Claim in safety — partially_supported
    ├─ used  claim/57978aae-fde3-44a4-9ee4-c35b37b0098f  Claim in safety — inconclusive  working
    ├─ used  claim/672787e0-48e6-4543-be3a-9bf8acbd3801  Claim in safety — supported
      ├─ derived_from  issue/notice@b90cab31cadf  Issued notice
      ├─ derived_from  issue/info_card@b0a29a724b80  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@9a96b1160ba9  Issued notice
      ├─ derived_from  issue/info_card@ca039f3fc178  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/chemistry.full@1
      ├─ informed_by  section/receptor-pharmacology.full@1
      └─ informed_by  section/neuroscience.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2520 with DOI

8 strong · 13 moderate · 4 weak

Compilations

22026-05-12T08:05:43.717Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:33:29.141Z

notice · info card · emergency

Searches

00 with no results

queries and counts on the build

Claims checked

6034 supported

34 supported · 26 not

Correspondence

0received

consent field ships in Phase 4

Edges

193

derivations recorded for this entity

Complete over 25 sources, 2 compilations, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/pargy-lad/archive

2Build

one panel per compilation run

generation run 2026-05-11

83 min failedmodel not recordedplan not recordedrun/4fe2bb7c…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0

selected by the model0

consumed as sources25

Verification

claims checked0

supported0

partially supported0

not supported0

inconclusive0

record
seen / partial
working

The model's own caveats

none raised on this run

Reproduce

inputs: 25 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: not recorded
streams: none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-12

52 min failedmodel pipeline-v5plan not recordedrun/6641cd01…

Selection

results seen0

selected by the model0

consumed as sources25

Verification

claims checked60

supported31

partially supported3

not supported0

inconclusive26

record
seen / partial
working

The model's own caveats

3 further caveats recorded as free text — readable on the working page

Reproduce

inputs: 25 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

60 claims by section — every cited sentence, checked against its source

safety20 · 11 ok

Claim in safety — inconclusiveinconclusiveworking →
In silico toxicity predictions have been generated for structurally distinct N1-acyl lysergamides (ALD-52, 1P-LSD, 1B-LSD, 1V-LSD, 1cP-LSD), yielding rat oral LD₅₀ estimates of 49–85 mg/kgsupported
In silico toxicity prediction for five N1-acyl LSD analogs. LD50 (rat): 49-85 mg/kg. s00204-025-04255-1
Claim in safety — inconclusiveinconclusiveworking →
Halpern and Pope reviewed 50 years of evidence and concluded that HPPD is genuine but uncommon, most commonly reported after LSD usesupported
Review of 20 studies on HPPD (1955-2001). HPPD is genuine but uncommon; most commonly reported after LSD use. s0376-8716(03)00036-8
Claim in safety — inconclusiveinconclusiveworking →
Predisposing factors include pre-existing anxiety, prior HPPD episodes, tinnitus, visual floaters, and concentration difficulties.supported
Predisposing factors: anxiety history, pre-drug tinnitus, eye floaters, concentration problems. 7854_2016_457
Tolerance to psychedelic effects develops rapidly following a single administration, driven by 5-HT₂A receptor downregulation in the frontal cortexpartially supported
Repeated DOI produces tolerance to HTR via 5-HT2A downregulation. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
The tolerance mechanism is independent of β-arrestin-2 signaling and produces complete cross-tolerance between LSD and DOI.supported
Cross-tolerance between DOI and LSD. Mechanism independent of beta-arrestin-2. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Tramadol acts as a weak serotonin reuptake inhibitor in addition to its opioid agonist activitysupported
Tramadol is a weak serotonin reuptake inhibitor. pmid:16051647
Combining tramadol's serotonin reuptake inhibition with PARGY-LAD's 5-HT₂A agonism and presumed 5-HT₁A activity creates a pharmacologically plausible risk for serotonin toxicity syndromesupported
Warning associated with serotonergic antidepressants and tramadol due to potential serotonin syndrome drug-drug interaction. 0897190013504957
Claim in safety — inconclusiveinconclusiveworking →
Based on the CYP1A2/CYP3A4 metabolic pathway inferred from AL-LAD and ETH-LAD, potent inhibitors of these enzymes (fluvoxamine, ciprofloxacin for CYP1A2; ketoconazole, ritonavir for CYP3A4) may increase PARGY-LAD plasma levelssupported
CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Concurrent tramadol use: serotonin toxicity risk via dual serotonergic mechanismsupported
Warning associated with serotonergic antidepressants and tramadol due to potential serotonin syndrome drug-drug interaction. 0897190013504957
Prior HPPD episodes or predisposing factors (anxiety disorders, pre-existing visual disturbances, tinnitus)supported
Predisposing factors: anxiety history, pre-drug tinnitus, eye floaters, concentration problems. 7854_2016_457
Severe hepatic impairment: if metabolism proceeds via CYP1A2/CYP3A4 as with structural analogs, hepatic impairment may significantly alter clearancesupported
CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9

pharmacology14 · 10 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Activation of 5-HT₂A receptors — particularly on layer V pyramidal neurons of the prefrontal cortex — triggers Gq-mediated phospholipase C signaling, activating downstream MAPK/ERK and protein kinase C cascadessupported
Active-state structure of 5-HT2A bound to 25-CN-NBOH hallucinogen. Determinants for 5-HT2A-Gq interaction. j.cell.2020.08.024
This mechanism is established as the primary pharmacological driver of classical psychedelic effects, confirmed for LSD through both receptor-blocking studies with ketanserin and structural biology.supported
Crystal structure of LSD in complex with 5-HT2B receptor. EL2 lid mechanism explains slow LSD dissociation. j.cell.2016.12.033
This mechanism is established as the primary pharmacological driver of classical psychedelic effects, confirmed for LSD through both receptor-blocking studies with ketanserin and structural biology.supported
X-ray crystal structures of 5-HT2A with LSD and methiothepin. Determinants for 5-HT2A-Gq interaction. j.cell.2020.08.024
The crystal structure of LSD bound to the 5-HT₂B receptor reveals an extracellular loop 2 (EL2) "lid" that closes over the bound ligand, explaining LSD's exceptionally slow dissociation kinetics (receptor residence time on the order of hours)supported
Crystal structure of LSD in complex with 5-HT2B receptor. EL2 lid mechanism explains slow LSD dissociation. LSD dissociates exceptionally slow from both 5-HT2B and 5-HT2A. j.cell.2016.12.033
Secondary targets, inferred from lysergamide class pharmacology, include 5-HT₁A partial agonism, dopamine D₂ partial agonism (Ki ≈ 100–400 nM for LSD), and α₂ adrenergic receptor activitysupported
Psychedelics have potent actions at nearly every serotonin, dopamine, and adrenergic receptor. j.neuron.2025.06.012
Secondary targets, inferred from lysergamide class pharmacology, include 5-HT₁A partial agonism, dopamine D₂ partial agonism (Ki ≈ 100–400 nM for LSD), and α₂ adrenergic receptor activitysupported
LSM-775 acts as a nonselective agonist at 5-HT1A and 5-HT2A receptors. dta.2222
The polypharmacology profile of 41 classical psychedelics across 318 GPCRs demonstrates that lysergamides as a class engage nearly every serotonin, dopamine, and adrenergic receptor subtypesupported
41 classical psychedelics profiled against 318 human GPCRs. Psychedelics have potent actions at nearly every serotonin, dopamine, and adrenergic receptor. j.neuron.2025.06.012
The compound does not act through monoamine reuptake inhibition or dopamine transporter binding, distinguishing it pharmacologically from stimulants.supported
Serotonergic psychedelics act via 5-HT2A. s00204-020-02693-7
Claim in pharmacology — inconclusiveinconclusiveworking →
The duration of subjective effects (8–12 hours for LSD) considerably exceeds what plasma half-life would predict, a phenomenon attributed to prolonged receptor occupancy via the EL2 lid mechanismsupported
EL2 lid mechanism explains slow LSD dissociation. LSD dissociates exceptionally slow from both 5-HT2B and 5-HT2A. j.cell.2016.12.033
Claim in pharmacology — inconclusiveinconclusiveworking →
Wagmann et al. characterized the in vitro metabolism of the structural analogs AL-LAD and ETH-LAD, identifying CYP1A2 and CYP3A4 as the primary metabolizing enzymessupported
Metabolism of ... ETH-LAD, 1P-ETH-LAD, AL-LAD ... via N-dealkylation and hydroxylation. CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9
Claim in pharmacology — inconclusiveinconclusiveworking →

comparative-pharmacology6 · 4 ok

Recent lysergamide structure-activity work has demonstrated that structural modifications at and near N6 can dissociate hallucinogenic potency from neuroplasticity-promoting effects, though whether PARGY-LAD's propargyl modification achieves such dissociation is unknown.supported
LSD analogues with structural modifications can decouple plasticity from hallucinogenesis. pnas.2416106122
In the mouse head-twitch response assay — the standard behavioral proxy for 5-HT₂A-mediated psychedelic activity — AL-LAD shows ED₅₀ = 174.9 nmol/kg versus LSD ED₅₀ = 132.8 nmol/kgsupported
AL-LAD ED50 = 174.9 nmol/kg; LSZ ED50 = 114.2 nmol/kg (vs LSD ED50 = 132.8 nmol/kg). dta.1985
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
AL-LAD and ETH-LAD share a CYP1A2/CYP3A4 metabolic profilesupported
Metabolism of ... ETH-LAD, 1P-ETH-LAD, AL-LAD ... CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9
The 1P-AL-LAD prodrug undergoes in vivo conversion to AL-LAD, with documented metabolic pathways including depropionylation and ergoline hydroxylationsupported
1P-AL-LAD converts to AL-LAD in vitro (prodrug). Fourteen metabolites including N-dealkylation, hydroxylation, dihydrodiol formation. dta.3281

receptor-pharmacology6 · 4 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
The active-state cryo-EM structure of the LSD–5-HT₂A–Gq complex demonstrates the ergoline scaffold engaging transmembrane helices 3, 5, and 6 in a pose that stabilizes the Gq-coupled active statepartially supported
X-ray crystal structures of 5-HT2A with LSD and methiothepin. Determinants for 5-HT2A-Gq interaction. j.cell.2020.08.024
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
The comprehensive polypharmacology screen of 41 psychedelics across 318 GPCRs confirmed potent lysergamide activity at 5-HT₁A, 5-HT₂B, 5-HT₂C, 5-HT₆, 5-HT₇, dopamine D₁/D₂/D₃, and α₁/α₂ adrenergic receptorssupported
41 classical psychedelics profiled against 318 human GPCRs. Psychedelics have potent actions at nearly every serotonin, dopamine, and adrenergic receptor. j.neuron.2025.06.012
AL-LAD and LSM-775 demonstrate nonselective 5-HT₁A agonism, which can mask the head-twitch response in rodents and modify subjective experience character in humans.supported
LSM-775 acts as a nonselective agonist at 5-HT1A and 5-HT2A receptors. 5-HT1A activation masks head twitch response. dta.2222
The closest structural analog with published animal data, AL-LAD (N6-allyl), shows ED₅₀ = 174.9 nmol/kg in the mouse head-twitch response assay versus LSD ED₅₀ = 132.8 nmol/kgsupported
AL-LAD ED50 = 174.9 nmol/kg; LSZ ED50 = 114.2 nmol/kg (vs LSD ED50 = 132.8 nmol/kg). dta.1985

chemistry4 · 0 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

summary4 · 2 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
As a lysergamide sharing the core ergoline pharmacophore, PARGY-LAD is presumed to act primarily through 5-HT₂A receptor agonism, with likely secondary activity at 5-HT₁A, dopamine D₂, and adrenergic receptors characteristic of the lysergamide classsupported
Psychedelics have potent actions at nearly every serotonin, dopamine, and adrenergic receptor. j.neuron.2025.06.012
The compound is not habit-forming; tolerance develops rapidly through 5-HT₂A receptor downregulation, with cross-tolerance to other classical psychedelics and an estimated 14-day full reset periodpartially supported
Repeated DOI produces tolerance to HTR via 5-HT2A downregulation. Cross-tolerance between DOI and LSD. acschemneuro.2c00170

neuroscience2 · 1 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Recent work on lysergamide structure-activity relationships has shown that structural modifications at N6 and elsewhere can dissociate hallucinogenic potency from neuroplasticity-promoting effects, raising the question of whether PARGY-LAD's reduced psychedelic potency correlates with altered neuroplastogenic potential.supported
LSD analogues with structural modifications can decouple plasticity from hallucinogenesis. Promotes cortical spinogenesis. pnas.2416106122

pharmacokinetic-detail2 · 2 ok

In vitro metabolism of the structural analogs AL-LAD and ETH-LAD proceeds primarily through CYP1A2 and CYP3A4, with metabolic reactions including N-dealkylation, ergoline hydroxylation, dihydrodiol formation, and N6-substituent transformations.supported
Metabolism of ... ETH-LAD, 1P-ETH-LAD, AL-LAD ... via N-dealkylation and hydroxylation. CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9
Based on the CYP1A2/CYP3A4 metabolic pathway inferred from structural analogs, potent CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) and CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice) may increase PARGY-LAD plasma levelssupported
CYP1A2 and CYP3A4 as primary enzymes. s00216-018-1558-9

clinical-evidence1 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →

history1 · 0 ok

Claim in history — inconclusiveinconclusiveworking →

3Sources

25 consumed · sorted by year · feeds = sections resting on it

Sources
year	source	tier	status	feeds
2026	The toxicity of psychedelic LSD derivatives: in silico approach for 1cP-LSD and analogsJurowski K, Krosniak A, Kobylarz D, Fijalkowska O · Archives of Toxicologydoi:10.1007/s00204-025-04255-1	moderate	consumed	1 section
2025	Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potentialTuck JR, Dunlap LE, Khatib YA, et al., Olson DE · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.2416106122	moderate	consumed	2 sections
2025	The polypharmacology of psychedelics reveals multiple targets for potential therapeuticsJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL · Neurondoi:10.1016/j.neuron.2025.06.012	strong	consumed	3 sections
2024	PARGY-LAD — PsychonautWikiurl:d39c060e9934d744	weak	consumed	cited only
2024	PARGY-LAD — Wikipediaurl:a7b0465d79b6efbb	weak	consumed	cited only
2024	PARGY-LAD PubChem Compound EntryPubChempmid:139030999	moderate	consumed	1 section
2022	Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LADBrandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Whitelock K, Stratford A, Auwärter V, Halberstadt AL · Drug Testing and Analysisdoi:10.1002/dta.3281	moderate	consumed	1 section
2022	Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatmentDoyle MA, Ling S, Lui LMW, et al., McIntyre RS · Expert Opinion on Drug Safetydoi:10.1080/14740338.2022.2063273	strong	consumed	1 section
2022	Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Micede la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.2c00170	moderate	consumed	2 sections
2020	Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7	strong	consumed	2 sections
2020	Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024	strong	consumed	2 sections
2019	In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening proceduresWagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR · Analytical and Bioanalytical Chemistrydoi:10.1007/s00216-018-1558-9	moderate	consumed	4 sections
2019	Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjectsHolze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, Liechti ME · British Journal of Clinical Pharmacologydoi:10.1111/bcp.13918	strong	consumed	1 section
2018	A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPDHalpern JH, Lerner AG, Passie T · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2016_457	moderate	consumed	1 section
2018	Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL · Drug Testing and Analysisdoi:10.1002/dta.2222	moderate	consumed	2 sections
2017	Crystal Structure of an LSD-Bound Human Serotonin ReceptorWacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL · Celldoi:10.1016/j.cell.2016.12.033	moderate	consumed	2 sections
2017	Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profileConey LD, Maier LJ, Ferris JA, Winstock AR, Barratt MJ · Human Psychopharmacologydoi:10.1002/hup.2599	moderate	consumed	1 section
2017	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsDolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-017-0513-9	strong	consumed	1 section
2017	Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL · Drug Testing and Analysisdoi:10.1002/dta.1985	moderate	consumed	2 sections
2016	PsychedelicsNichols DE · Pharmacological Reviewsdoi:10.1124/pr.115.011478	strong	consumed	6 sections
2014	Reports on PARGY-LAD (newly offered lysergamide) — Bluelight.orgurl:23284f423c322935	weak	consumed	cited only
2014	Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?Park SH, Wackernah RC, Stimmel GL · Journal of Pharmacy Practicedoi:10.1177/0897190013504957	weak	consumed	1 section
2005	Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.Gillman PK · British Journal of Anaesthesiapmid:16051647	strong	consumed	1 section
2003	Hallucinogen persisting perception disorder: what do we know after 50 years?Halpern JH, Pope HG · Drug and Alcohol Dependencedoi:10.1016/s0376-8716(03)00036-8	moderate	consumed	1 section
1985	Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivativesHoffman A, Nichols DE · Journal of Medicinal Chemistrydoi:10.1021/jm00147a022	moderate	consumed	4 sections

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-12revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/pargy-lad/version/1
0022026-06-04proposal29 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
29 items in this filing
- contraindication · other
- contraindication · other
- contraindication · neurological
- contraindication · cardiovascular
- contraindication · psychiatric
- contraindication · pregnancy_breastfeeding
- contraindication · hepatic
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · resolution
- timeline · oral · afterglow
psx:substance/pargy-lad/proposal/contraindication/614775c8-8e46-4f75-9ab0-35e0692ec9a5
0032026-06-04publicationPublication — backfill
psx:substance/pargy-lad/pub/aad61c78-1889-4631-b42b-89dcac2783cd

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
emergency	c15c760aabf6f0fcf5b6fc6b…	2026-10-19 20:33	Revision 1	current
info_card	ca039f3fc17813d46264d501…	2026-10-19 20:33	Revision 1	current
notice	9a96b1160ba9098f7cde020c…	2026-10-19 20:33	Revision 1	current
emergency	3f0909c25c714d225b4bb3e3…	2026-09-04 04:31	Revision 1	superseded2026-10-19
info_card	b0a29a724b80e604af8ff8fa…	2026-09-04 04:31	Revision 1	superseded2026-10-19
notice	b90cab31cadf5bd920a3dc6c…	2026-09-04 04:31	Revision 1	superseded2026-10-19

PARGY-LAD

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-11

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

generation run 2026-05-12

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify

research

draft

audit

verify

simplify